CymaBay Therapeutics
7999 Gateway Blvd.
Suite 130
Newark
California
94560
United States
Tel: 510-293-8800
Website: http://www.cymabay.com/
Email: info@cymabay.com
About CymaBay Therapeutics
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH).
157 articles about CymaBay Therapeutics
-
CymaBay Therapeutics Announces Positive Interim Results From Its Ongoing Low-Dose Phase II Study Of Seladelpar In Patients With Primary Biliary Cholangitis
7/17/2017
-
CymaBay Therapeutics Announces The Appointment Of Klara Dickinson As Senior Vice President, Regulatory Affairs And Quality Assurance And The Promotion Of Daniel Menold To Vice President, Finance
6/26/2017
-
CymaBay Therapeutics Reports First Quarter 2017 Financial Results And Provides Corporate Update
5/12/2017
-
CymaBay Therapeutics To Report First Quarter 2017 Financial Results On Thursday, May 11
5/4/2017
-
Bay Area's CymaBay Therapeutics CEO To Retire, Interim Leader Named
3/29/2017
-
Kowa Pharmaceuticals America Announces Agreement With CymaBay Therapeutics To License Gout Compound
1/4/2017
-
CymaBay Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results
3/30/2016
-
CymaBay Therapeutics To Present At The Biotech Showcase 2016
1/6/2016
-
CymaBay Therapeutics Announces Participation At Three Upcoming Investor Conferences
11/16/2015
-
CymaBay Therapeutics Announces The Initiation Of A Phase II Study Of MBX-8025 In Patients With Primary Biliary Cholangitis/Cirrhosis
11/10/2015
-
CymaBay Therapeutics To Present Results From Two Arhalofenate Phase II Studies At The American College of Rheumatology Annual Meeting, November 6 - 11
11/5/2015
-
CBAY: LifeSci Capital Initiates Coverage of CymaBay Therapeutics
10/26/2015
-
CymaBay Therapeutics Announces The Appointment Of Robert J. Wills, Ph.D., As Chairman Of The Board Of Directors
10/9/2015
-
CymaBay Therapeutics To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
9/3/2015
-
CymaBay Therapeutics To Ring The Nasdaq Stock Market Closing Bell
5/15/2015
-
Vince & Associates Clinical Research Completes CymaBay Therapeutics’ Clinical Trial Of Arhalofenate In Combination With Febuxostat
3/3/2015
-
With Promising New Gout Treatment In Its Pipeline, 2015 Will Be Big Year For CymaBay Therapeutics
11/14/2014